Medisyn Technologies, Inc. Awarded Phase I SBIR Grant by Department of Defense to Discover and Develop Novel NSAIDs with Reduced GI Toxicity

MINNEAPOLIS--(BUSINESS WIRE)--Medisyn Technologies today announced that the company was recently awarded a Small Business Innovation Research (SBIR) Phase I grant from the Department of Defense (DoD) to discover and develop new non-steroidal anti-inflammatory drugs (NSAIDs) with reduced gastrointestinal toxicity. NSAIDs devoid of GI toxicity that may be potentially available without a prescription (over-the-counter) enables easier access for deployed military personnel.

Back to news